Lord, Abbett & Co. LLC recently announced the acquisition of new stake in NextCure Inc. (NASDAQ:NXTC). The institutional investor has increased its shareholding in the Healthcare company by 48.19% to 2.14 million shares with purchase of 0.7 million shares. This fresh investment now brings its stake to 7.77% valued currently at $66.71 million. In addition, Great Point Partners LLC raised its holdings by 0.18 million to 1.31 million shares. And AllianceBernstein LP has lifted its position by 17.94% or 0.19 million shares – to 1.25 million shares.
With over 6.62 million NextCure Inc. (NXTC) shares trading Monday and a closing price of $8.15 on the day, the dollar volume was approximately $53.93 million. The shares have shown a negative weekly performance of -60.21% and its price on 07/13/20 lost nearly -54.42%. Currently, there are 27.51M common shares owned by the public and among those 23.78M shares have been available to trade.
The analysts have set the share’s price value over the next 12 months at a high of $61.00 and a low of $11.00 should the stock experience a downside. Incidentally, analysts’ outlook for the NextCure Inc. stock is 2.10 for the next 12 months. But an upside of 86.64% will see the stock hit the forecast high price target while mean target price for the stock is $31.00.
Insiders at the company have transacted a total of 3 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 3 of these insider trades were purchases, accounting for 205,234 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in NextCure Inc. are Vanguard Total Stock Market Index, AB Small Cap Growth Portfolio, and PGIM Jennison Health Sciences Fun. Vanguard Total Stock Market Index owns 0.35 million shares of the company’s stock, all valued at over $10.83 million. The company sold 6420.0 shares recently to bring their total holdings to about 1.26% of the shares outstanding. AB Small Cap Growth Portfolio bought 20470.0 shares to see its total holdings expand to 0.32 million shares valued at over $10.13 million and representing 1.18% of the shares outstanding. PGIM Jennison Health Sciences Fun now owns shares totaling to 1.12% of the shares outstanding.
Shares of NextCure Inc. (NASDAQ: NXTC) opened at $12.75, down -$5.13 from a prior closing price of $17.88. However, the script later closed the day at $8.15, down -54.42%. The company’s stock has a 5-day price change of -60.21% and -77.37% over the past three months. NXTC shares are trading -85.53% year to date (YTD), with the 12-month market performance down to -51.43% lower. It has a 12-month low price of $16.04 and touched a high of $109.00 over the same period. Currently, 6.62 million shares have been traded, compared to an average intraday trading volume of 360.19K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -63.32%, -71.13%, and -78.85% respectively.
Institutional ownership of NextCure Inc. (NASDAQ: NXTC) shares accounts for 82.60% of the company’s 27.51M shares outstanding. Mutual fund holders own 16.05%, while other institutional holders and individual stakeholders account for 40.32% and 12.07% respectively.
It has a market capitalization of $228.04M. The earnings-per-share (ttm) stands at -$1.10. Price movements for the stock have been influenced by the stock’s volatility, which stands at 19.85% over the week and 11.16% over the month.
Analysts forecast that NextCure Inc. (NXTC) will achieve an EPS of -$0.52 for the current quarter, -$0.6 for the next quarter and -$2.58 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.66 while analysts give the company a high EPS estimate of -$0.35. Comparatively, EPS for the current quarter was -$0.61 a year ago. Earnings per share for the fiscal year are expected to decrease by -106.80%, and -62.30% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 9 brokerage firm advisors rate NextCure Inc. (NXTC) as a “Moderate Buy” at a consensus score of 2.10. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 6 of the 9 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the NXTC, a number of firms have released research notes about the stock. SunTrust stated their Hold rating for the stock in a research note on July 13, 2020, with the firm’s price target at. ROTH Capital coverage for the NextCure Inc. (NXTC) stock in a research note released on July 13, 2020 offered a Neutral rating with a price target of. The Benchmark Company was of a view on June 01, 2020 that the stock is Hold, while BofA/Merrill gave the stock Neutral rating on June 01, 2020, issuing a price target of $62- $40. JMP Securities on their part issued Mkt Outperform rating on May 26, 2020.